Zacks Investment Research upgraded Loxo Oncology Inc (NASDAQ:LOXO) to Hold in a report released today.
- Updated: October 9, 2016
Zacks Investment Research has upgraded Loxo Oncology Inc (NASDAQ:LOXO) to Hold in a report released on 10/05/2016.
Yesterday Loxo Oncology Inc (NASDAQ:LOXO) traded -3.26% lower at $22.97. The company’s 50-day moving average is $26.35 and its 200-day moving average is $25.43. The last closing price is down -12.45% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 67,604 shares of the stock traded hands, down from an average trading volume of 82,923
See Chart Below
Loxo Oncology Inc has a 52 week low of $16.36 and a 52 week high of $35.00 The company’s market cap is currently $0.
Also covering Loxo Oncology Inc's target, a total of 4 equity analysts have released a ratings update on LOXO. The one year target is $30.00 with three equity analysts rating the company a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally zero analysts rating the company a sell.
More About Loxo Oncology Inc (NASDAQ:LOXO)
Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.